Furthermore, a few case reports described the use of JAK inhibitors in ILDs related to other autoimmune diseases (like STING-associated vasculopathy and systemic idiopathic juvenile arthritis).78,79 However, most human clinical data on JAK inhibition in ILD come from RA patients with ILD, since JAK inhibition was approved for RA first. This evidence concerns the gene STING1 and rheumatoid arthritis.